| Ytd | -35.36% | |
| 1y | -10.79% |
| Open | 0.75 | Prev Close | 0.72 | Low | 0.70 | High | 0.72 | Mkt Cap | 18.70M |
| Vol | 12.17K | Avg Vol | 78.34K | EPS | -6.52 | P/E | N/A | Forward P/E | -0.84 |
| Beta | 0.40 | Short Ratio | 1.60 | Inst. Own | 33.14% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 0.81 | 200-d Avg | 0.95 | 1yr Est | 5.00 |
AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical comp
AEON Biopharma (AMEX:AEON) reported quarterly losses of $(0.29) per share which missed the analyst c
AEON Biopharma (AMEX:AEON) reported quarterly losses of $(3.72) per share. This is a 199.2 percent d
FDA provided constructive feedback on Company's analytical similarity strategy under the 351(k)
Shares of Nuvve Holding Corp. (NASDAQ: NVVE) fell sharply during Monday’s session after the company
Shares of United Parcel Service, Inc. (NYSE: UPS) fell sharply during Tuesday’s session after the co
Gainers NanoVibronix, Inc. (NASDAQ: NAOV) shares jumped 89.5% to $2.7852 after the company report